Entity

Time filter

Source Type

London, United Kingdom

PA Consulting Group is a consultancy specialising in management consulting, technology and innovation. It has clients in both the private and public sector including local and national Governments and the defence sector. It has offices in Europe, the Nordics, the United States, the Persian Gulf and Asia Pacific and operates as an employee-owned company. Wikipedia.


Guidi B.T.U.,PA Consulting Group
Journal of Oncology Practice | Year: 2011

There are many obvious differences for billing and reimbursement for outpatient oncology services in the hospital outpatient department versus in the office-based setting. The details can be difficult for hospitals to master because outpatient oncology is just one of many service lines to be billed. And the coding, billing, and payment details represent only part of the challenge for hospitals. Institutions are large and complex organisms, with many departments handling components of the entire continuum of delivering and billing for services. This often leads to significant fragmentation or miscommunication. For example, if the department responsible for maintaining the system to record charges (the charge master) is not well informed regarding changes in coding and billing requirements, important codes or code definitions may not be current and accurate, making it impossible for charge entry staff to choose the correct items. Or if the department responsible for patient registration is not aware of payer nuances regarding the use of specific drugs for certain diagnoses, they will not know that a predetermination of insurance coverage is needed. Finally, the pharmacy charge entry system may record the units of drug dispensed, but if those units do not match the Healthcare Common Procedure Coding System unit definition of billable dose, then drug charges can be grossly under- or overstated. Thus, hospitals frequently find it extremely difficult to match the detailed expertise that most office-based practices have developed through years of specialty focus. Copyright © 2011 by American Society of Clinical Oncology. Source


Hurko O.,PA Consulting Group | Hurko O.,Inc. Central Office
Neurochemistry International | Year: 2012

The last fifteen years have witnessed a major strategic shift in drug discovery away from an empiric approach based on incremental improvements of proven therapies, to a more theoretical, target-based approach. This arose as a consequence of three technical advances: (1) generation and interpretation of genome sequences, which facilitated identification and characterization of potential drug targets; (2) efficient production of candidate ligands for these putative targets through combinatorial chemistry or generation of monoclonal antibodies; and (3) high-throughput screening for rapid evaluation of interactions of these putative ligands with the selected targets. The basic idea underlying all three of these technologies is in keeping with Marshall Nirenberg's dictum that science progresses best when there are simple assays capable of generating large data sets rapidly. Furthermore, practical implementation of target-based drug discovery was enabled directly by technologies that either were originated or nurtured by Marshall, his post-docs and fellows. Chief among these was the genetic code. Also important was adoption of clonal cell lines for pharmacological investigations, as well as the use of hybridomas to generate molecular probes that allowed physical purchase on signaling elements that had previously been only hypothetical constructs. Always the pure scientist, Marshall's contributions nevertheless enabled fruitful applications in the pharmaceutical industry, several of them by his trainees. Both the successes and the shortcomings of target-based drug discovery are worthy of consideration, as are its implications for the choices of therapeutic goals and modalities by the pharmaceutical industry. © 2011 Elsevier Ltd. All rights reserved. Source


Gilby S.,PA Consulting Group
Fuel Cells Bulletin | Year: 2013

While current PEM fuel cell research is mainly focused on reducing system costs and improving efficiency, less attention is being paid to the possibilities offered by mass-production and economies of scale. PA Consulting Group has identified over-complicated components, fragmented supply chains, and a lack of significant national organisation as rate-limiting processes in the development of the UK fuel cell industry. © 2013 Elsevier Ltd. Source


Jeanes P.,PA Consulting Group
Traffic Engineering and Control | Year: 2010

Cars are a big problem for the Government's Carbon Reduction Strategy for Transport which was published last July. This proposes a process of carbon budgets to address global climate change and achieve a projected reduction of carbon emissions of 34% by 2020 and 80% by 2050. Transport has the second largest budget, with 17% of all UK emissions. Of the total transport carbon emissions, 58.3% are from cars, making the reduction of car emissions one of the most challenging targets. So is such a reduction feasible? Source


Guidi T.U.,PA Consulting Group
Journal of Oncology Practice | Year: 2013

For the past few years, there has been a rising trend to shift outpatient infusion services from the private practice setting to the hospital outpatient setting. Numerous and complex factors are driving this trend. More complex however are the myriad details required to operationalize a change in structure and ensure that all parties are clear and comfortable with the outcome. Copyright © 2013 by American Society of Clinical Oncology. Source

Discover hidden collaborations